Lakes Research, LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$8,414	4
2023	Research	$61,748	36
2022	Research	$51,340	20
2021	Research	$7,963	4
2019	Research	$489	3

Breakdown

Who paid Research payments · program years 2019–2024

CSL Behring $82,433 43 payments
Apellis Pharmaceuticals, Inc. $30,536 16 payments
MorphoSys AG $16,250 4 payments
Incyte Corporation $736 4 payments

Studies the money was for Research payments · program years 2019–2024

A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis $82,433 43 payments
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind $10,500 1 payment
Pegcetacoplan Long Term Safety and Efficacy Extension Study $8,999 4 payments
Ltse $7,216 2 payments
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) $5,874 3 payments
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) $5,750 3 payments
Pegcetacoplan Long Term Safety and Efficacy Extension Study $5,303 4 payments
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) $2,643 2 payments
Prospective, Non Interventional Study of Disease Progression and Treatment of Patients With Polycythemia Vera in United States Academic Or Community Clinical Practices $736 4 payments
Plaudit $500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.